RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
RenovoRx, Inc.NASDAQ: RNXT
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 15.7% from a year ago
Net receivables stood at $280K at the end of Q1 FY2026, up 15.7% from a year earlier and up 101.4% from the prior quarter.
Context
- Net receivables amounted to 2.0% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +15.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 139K USD
- Year-over-year change
- +223.3%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 139K | +223.3% |
| FY2024 | 2024-12-31 | 43K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 net receivables of $280K is the 2nd highest of the 6 companies compared; the peer median is $0.
- Its year-over-year change of +15.7% is the highest of 3, against a peer median of -82.8%.
- Net receivables amounts to 2.0% of total assets for RNXT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $4.65M | -65.7% | -12.6% | 4.3% | |
| Mar 2026 | $280K | +15.7% | — | 2.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RNXT) | $0 | -82.8% | -12.6% | 0.0% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.